

B

Α


## Figure S1. Loss of Setd2 in ISCs exacerbates DSS-induced colitis in mice

(A) Relative mRNA expression levels of Setd2 in whole colon of Setd2<sup>ISC-KO</sup> and Setd2<sup>f/f</sup> mice were determined by RT-qPCR (n =5 per genotype).

(B) Relative mRNA expression levels of pro-inflammatory cytokines in whole colon of Setd2<sup>ISC-KO</sup> and Setd2<sup>f/f</sup> mice

1


were determined by RT-qPCR (n = 5 per genotype).



## Figure S2. Loss of Setd2 reduces ISCs proliferation in mice.

(A) Experimental layout of Setd2<sup>ISC-KO</sup> mouse model. The model was induced by tamoxifen intraperitoneal injection for 5 consecutive days. (n=5).

2



## Figure S3. Targeted delivery of Grem1 by AT-MSC effectively reduces colitis

(A) Experimental layout of MSC-Grem1 treatment in the colitis. The colitis model was induced by one dose of tamoxifen and 2.5% DSS in drinking water for 5 consecutive days. Mice received an intravenous injection of  $1 \times 10^6$  AT-MSCs (n=4) or PBS (n=4) on day 3.




Figure S4. Targeted delivery of Grem1 by AT-MSC increases ISCs number and inhibits BMP signaling

(A) Relative mRNA expression levels of ISCs signature gene expression in the whole colon of Setd2<sup>ISC-KO</sup> and Setd2<sup>f/f</sup> mice


were fed 2.5% DSS in drinking water and injected  $1*10^6$  MSCs (n=4 per genotype). Data represent means  $\pm$  S.D.

(B) Record of colon tissues collected on day 9 from Setd2<sup>ISC-KO</sup> and Setd2<sup>f/f</sup> mice were fed 2.5% DSS in drinking water and

injected  $1*10^6$  MSCs. (n = 4 per genotype).

(C) Relative mRNA expression levels of cell cycle arrest genes in the Lgr5+ cells of colon from Setd2<sup>ISC-KO</sup> and Setd2<sup>f/f</sup> mice were fed 2.5% DSS in drinking water and injected 1\*10<sup>6</sup> MSCs. Data represent means  $\pm$  S.D., and statistical significance was

determined by a Student t-test. \*, p < .05; \*\*, p < .01; \*\*\*, p < .001.



## Figure S5. Targeted delivery of IL-10 by AT-MSC reduces colitis

(A) Experimental layout of MSC-IL-10 treatment in the colitis. The colitis model was induced by one dose of tamoxifen and 2.5% DSS in drinking water for 5 consecutive days. Mice received an intravenous injection of  $1 \times 10^6$  AT-MSCs (n=4) or PBS (n=4) on day 3.




Figure S6. Targeted delivery of IL-10 by AT-MSCs upregulated the protein level of IL-10 in inflammatory colon. (A) Immunofluorescence staining of IL-10 of colon tissues collected on day 9 from Setd2<sup>f/f</sup> mice were fed 2.5% DSS in drinking water and injected  $1 \times 10^6$  AT-MSCs. (n = 4 per genotype). Scale Bars: 50 µm. Data represent means  $\pm$  S.D., and statistical significance was determined by a student t-test. \*, p < .05; \*\*, p < .01; \*\*\*, p < .001.